Evidence map›Paper›PMID 38078592›Full record

ReviewDiabetes care2024

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.

American Diabetes Association Professional Practice Committee

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 261 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
261citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06865885 phase4recruitingstarted 2025, after this paper: background citation

Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering

Ran2025Enrolled100Registered outcomes4Posted comparisons0ConditionsCardiometabolic Syndrome, Drug Interactions, LDL-Cholersterol Lowering, Primary PreventionArmsInclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
PMID 27754879PMID 32187462PMID 37227328PMID 10403851PMID 12654605PMID 32197277PMID 33663735PMID 35175848PMID 35290077PMID 36692678other papers from this trial
Open the trial in the graph
NCT07667517 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Finerenone for the Early Regression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

TypeinterventionalSponsorFirst Affiliated Hospital of Zhejiang UniversityRan2026 to 2027Enrolled148ConditionsAlbuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney DiseasesArmsFinerenone (BAY 94-8862), Placebo
3 · Its place in the literature

Who cites it

261 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Health-related quality of life in racial and ethnic minority adults with type 2 diabetes: validity and responsiveness of the EQ-5D-3L.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Review

201 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

American Diabetes Association Professional Practice Committee

Funding

NIDDK NIH HHS K23 DK121942
6 · The paper itself

Abstract

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

Indexed as

Cardiovascular DiseasesDiabetes MellitusEndocrinologyHumansReference StandardsSocieties, MedicalStandard of Care

Identifiers

PMID38078592
PMCPMC10725811

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.